MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: ‘We Were Surprised By Reported Deaths’
MacroGenics Inc (NASDAQ:MGNX) released interim data from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo). TAMARACK is being conducted in previously treated patients with metastatic castration-resistant prostate cancer (mCRPC). MacroGenics reported five deaths (fatal outcome) during the trial. It also reported over 50% rate of grade 3, or worse, adverse events in both dose cohorts (2 […]